| Proportion (%) of patients receiving co-therapies | ||
---|---|---|---|
 | Before rituximab | During rituximab | After rituximab during follow-upa |
Immunosuppressives | 98.1 | 41.2 | 78.6 |
Prednisolone | 68.9 | 66.1 | 58.9 |
with glucocorticoid bolus therapy | 17.0 | 1.25 | 1.6 |
Methylprednisolone | 25.4 | 13.2 | 4.3 |
Methotrexate | 22.1 | 6.9 | 8.9 |
Cyclophosphamide | 36.2 | 8.15 | 3.2 |
Azathioprine | 38.1 | 11.9 | 10.8 |
Mycophenolate mofetil | 27.6 | 15.0 | 17.8 |
Intravenous Ig | 17.0 | 3.4 | 5.1 |
Plasmapheresis | 13.8 | 3.4 | 0.8 |
Other immunosuppressives | 16.0 | 5.3 | 5.4 |